We are live on
!
Find out more
Galectin Therapeutics
GALT
GALT
60 hedge funds and large institutions have $17.4M invested in Galectin Therapeutics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
215% more call options, than puts
Call options by funds: $63K | Put options by funds: $20K
66% more capital invested
Capital invested by funds: $10.5M → $17.4M (+$6.91M)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more ownership
Funds ownership: 12.22% → 15.22% (+3%)
0% more funds holding
Funds holding: 60 → 60 (0)
Holders
60
Holders Change
–
Holders Change %
0%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
12
Reduced
8
Closed
4
Calls
$63K
Puts
$20K
Net Calls
+$43K
Net Calls Change
-$31K
Top Buyers
Top Sellers
| 1 |
BlackRock
New York
|
-$72.9K |
| 2 |
AAS
Ameritas Advisory Services
Lincoln,
Nebraska
|
-$64.6K |
| 3 |
Millennium Management
New York
|
-$58.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$19.5K |
| 5 |
Neuberger Berman Group
New York
|
-$16.7K |
